Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 16, 2022
Catalyst Pharmaceuticals (CPRX) will release its Q4 and FY 2021 financial results on March 16, 2022, after market close. A conference call and webcast will follow on March 17, 2022, at 8:30 AM ET to discuss these results and provide a corporate update. The company's FIRDAPSE (amifampridine) Tablets, approved for treating adults with Lambert-Eaton myasthenic syndrome, is currently available in the U.S. and Canada. Catalyst emphasizes a commitment to developing innovative medicines for rare diseases.
- FIRDAPSE approved for LEMS, enhancing market presence.
- Webcast scheduled for March 17 to discuss financials and corporate updates.
- None.
The Company Will Host a Conference Call and Webcast on March 17, 2022, at 8:30 AM ET
CORAL GABLES, Fla., March 03, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that it will release its fourth quarter and full-year 2021 financial results after market close on Wednesday, March 16, 2022.
Catalyst's management team will host a conference call and webcast the following morning, Thursday, March 17, 2022, at 8:30 AM ET to discuss the Company's financial results and provide a corporate update.
Conference Call & Webcast Details
| Date/Time: | March 17, 2022, at 8:30 AM ET |
| US/Canada Dial-in Number: | (877) 407-8912 |
| International Dial-in Number: | (201) 689-8059 |
A webcast and accompanying materials will be accessible under the Investors section on the Company's website at www.catalystpharma.com. A replay of the webcast will be available on the Catalyst website for 30 days following the date of the event.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for fiscal year 2020 and its other filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
FAQ
When will Catalyst Pharmaceuticals release its Q4 2021 financial results?
What is the purpose of the conference call hosted by Catalyst Pharmaceuticals?
What time is the Catalyst Pharmaceuticals conference call?
What is FIRDAPSE and who is it approved for?
Is FIRDAPSE available in countries other than the US?
